Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy

Cairo University (CU)

Status: Enrolling

Conditions: Placenta Accreta Spectrum

Treatments: Other: placebo; Drug: oxytocin

Study type: Interventional

Funder types: Other

Identifiers

NCT06493968

Uterotonics in PASD

Details and patient eligibility

About

Objectives: To evaluate the effect of oxytocin in reducing intraoperative blood loss in patients with PAS disorders planned for cesarean hysterectomy.

Enrollment: 70 estimated patients

Sex: Female

Ages: 20 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Pregnancy of singleton living fetus
• Previous one or more cesarean sections
• Gestational age: > 32 weeks
• The following ultrasound markers such as "loss of clear retroplacental translucency", "myometrial thinning", "abnormal lacunae", "irregular bladder wall", "utero-vesicalhypervascularity".
• Preoperative hemoglobin more than 10 gm/dl
• Cases with PAS that will undergoing CS Hysterectomy

Exclusion criteria

• Maternal medical disorders e.g.: coagulation defects, cardiac diseases etc.....
• Any known or reported hypersensitivity to the used medication.
• All cases with spontaneous placental separation at laparotomy.
• All patients undergoing conservative management of PAS.
• All cases which necessitate emergency termination.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

70 participants in 2 patient groups, including a placebo group

Group (A)

Experimental group

Description:

Patients will be given uterotonics

Treatment:

Drug: oxytocin

Group (B)

Placebo Comparator group

Description:

Patients will not be given uterotonics

Treatment:

Other: placebo